

1

## **Appendix A: pCODR Clinician Conflict of Interest Declarations**

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Neil Chua
Name of drug and indication under review:	Pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma as monotherapy or in combination with platinum and FU chemotherapy
Conflict of Interest Declaration	
conflicts of interest. A registered clinician must decl	DDR process, all participants in the pCODR review process must disclose any are any potential conflicts of interest that may influence or have the appearance of interest declaration is requested for transparency — it does not negate or
Examples of conflicts of interest include, but are not	limited to:
gifts, and salary)	ry or other entities (e.g., educational or research grants, honoraria, ips with drug manufacturers or other interest groups.
Section A: Payment Received	
Have you received any payments over the previndirect interest in the drug under review?	rious two years from any company or organization that may have a direct or
⊠ Yes □ No	
If no, please go to Section B.	
2. What form of payment did you receive? (Check	all that apply.)
<ul> <li>Advisory role (e.g., advisory boards, hea technology assessment submission advi</li> </ul>	
☐ Conference attendance	☐ Research/educational grants
☐ Royalties	☐ Travel grants
☐ Gifts	☐ Sponsorship of events
	☐ Other, please specify:
⊠ Honoraria	☐ Other, please specify:

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following table.

Company	Nature or description of activities or interests	Check Appropriate Dollar Range			Range
		\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
Merck	National consultation meeting	$\boxtimes$			



## **Section B: Holdings or Other Interests**

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations	that
may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.	

No		
Section C: Affiliations	, Personal or Commercial Relationships	
Do you have personal or operation, subside	commercial relationships either with a drug or health technology manufactuliaries, affiliates, and associated corporations) or other interest groups? If tractions, and outline the nature of these relationships, in the following box.	yes, please provide the names of
No		
By checking this box. I h	ereby certify that the information that I have presented here is	П
	the best of my knowledge	Ш
Date	Neil Chua Name	



1

## **Appendix A: pCODR Clinician Conflict of Interest Declarations**

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Martin Smoragiewicz
Name of drug and indication under review:	Pembro+/-chemo in r/m H&N
Conflict of Interest Declaration	
conflicts of interest. A registered clinician must declar	DDR process, all participants in the pCODR review process must disclose any are any potential conflicts of interest that may influence or have the appearance of interest declaration is requested for transparency — it does not negate or
Examples of conflicts of interest include, but are not	t limited to:
	ry or other entities (e.g., educational or research grants, honoraria,
gifts, and salary)  • affiliations, or personal or commercial relationsh	ips with drug manufacturers or other interest groups.
Section A: Payment Received	
Have you received any payments over the previndirect interest in the drug under review?	vious two years from any company or organization that may have a direct or
□ Yes ⊠ No	
If no, please go to Section B.	
What form of payment did you receive? (Check	all that apply.)
<ul> <li>Advisory role (e.g., advisory boards, hea technology assessment submission advi</li> </ul>	·
☐ Conference attendance	☐ Research/educational grants
☐ Royalties	☐ Travel grants
☐ Gifts	☐ Sponsorship of events
☐ Honoraria	☐ Other, please specify:

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following table.

Company	Nature or description of activities or interests	Check Appropriate Dollar Range			Range
		\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000



Section B: Holdings or	Other Interests	
-	possession of stocks or options of more than \$10,000 (excluding met interest in the drug under review? If yes, please list them in the follows:	,
Section C: Affiliations,	Personal or Commercial Relationships	
parent corporation, subsidia	mmercial relationships either with a drug or health technology manuaries, affiliates, and associated corporations) or other interest groups ations, and outline the nature of these relationships, in the following	? If yes, please provide the names of
By checking this box, I her accurate and complete to	reby certify that the information that I have presented here is the best of my knowledge	
15/05/2020 Date	Martin Smoragiewicz	
Daid	inallic	



# Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Anna Spreafic	co	
Name of drug and indication under review:	Pembrolizum	ab	
Conflict of Interest Declaration			
To maintain the objectivity and credibility of the pCo conflicts of interest. A registered clinician must deci of influencing the information submitted. A conflict of preclude the use of the clinician input.	lare any potentia	I conflicts of interest that	may influence or have the appearance
Examples of conflicts of interest include, but are no	t limited to:		
<ul> <li>financial support from the pharmaceutical indusing gifts, and salary)</li> </ul>	try or other entit	es (e.g., educational or re	esearch grants, honoraria,
affiliations, or personal or commercial relationsh	ips with drug ma	anufacturers or other inte	rest groups.
Section A: Payment Received			
Have you received any payments over the previndirect interest in the drug under review?	vious two years	from any company or org	anization that may have a direct or
⊠ Yes □ No			
If no, please go to Section B.			
2. What form of payment did you receive? (Check	all that apply.)		
Advisory role (e.g., advisory boards, hea technology assessment submission advi		m or Operating Funding vebsite)	
☐ Conference attendance	☐ Resea	rch/educational grants	
☐ Royalties	☐ Travel	grants	
☐ Gifts	☐ Spons	orship of events	
☐ Honoraria	☐ Other,	please specify:	Same and the same a

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following table.

Company	Nature or description of activities or interests	Check Appropriate Dollar Range				
		\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000	
MERCK	Ad board	×				



Section B: Holdings or Other Interests	
Have you received or are in possession of stocks or options of more	re than \$10,000 (excluding mutual funds) for organizations that

may have a direct or indirect interest in the drug under review? If yes, please list them in the following box. I do receive research funding from MERCK to run clinical trials. Section C: Affiliations, Personal or Commercial Relationships Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box. no By checking this box, I hereby certify that the information that esented here is X accurate and complete to the best of my knowledge June 10, 2020 Name



## **Appendix A: pCODR Clinician Conflict of Interest Declarations**

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	Aaron Hansen
Name of drug and indication under review:	Pembrolizumab – RM HNSCC
Conflict of Interest Declaration	
conflicts of interest. A registered clinician must decl	DDR process, all participants in the pCODR review process must disclose any are any potential conflicts of interest that may influence or have the appearance of interest declaration is requested for transparency — it does not negate or
Examples of conflicts of interest include, but are not	t limited to:
<ul> <li>financial support from the pharmaceutical indust gifts, and salary)</li> </ul>	ry or other entities (e.g., educational or research grants, honoraria,
	ips with drug manufacturers or other interest groups.
Section A: Payment Received	
Have you received any payments over the previndirect interest in the drug under review?	vious two years from any company or organization that may have a direct or
If no, please go to Section B.	
2. What form of payment did you receive? (Check	all that apply.)
Advisory role (e.g., advisory boards, hea technology assessment submission advi	·
☐ Conference attendance	☐ Research/educational grants
☐ Royalties	☐ Travel grants
☐ Gifts	☐ Sponsorship of events
☐ Honoraria	☐ Other, please specify:

3. Please provide the names of companies and organizations, and the amounts of the payments, in the following table.

Company	Nature or description of activities or interests	Check Appropriate Dollar Range			Range
		\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
Merck	Advisory Role	$\boxtimes$			
GSK	Advisory Role	$\boxtimes$			



### **Section B: Holdings or Other Interests**

Date

Н	lave you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that			
m	may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.			
	No			

Section C: Affiliations, Personal or Commercial Relationships	
Do you have personal or commercial relationships either with a drug or health technology manufaparent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? the companies and organizations, and outline the nature of these relationships, in the following be	If yes, please provide the names of
No	
By checking this box, I hereby certify that the information that I have presented here is accurate and complete to the best of my knowledge	$\boxtimes$
13 May 2020	

Aaron Hansen

Name